{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:04:42Z","timestamp":1782489882804,"version":"3.54.5"},"reference-count":135,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1124\/jpet.118.254979","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T21:18:00Z","timestamp":1549660680000},"page":"636-646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes"],"prefix":"10.1016","volume":"370","author":[{"given":"Bruna","family":"Corradetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Steven","family":"Conlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.118.254979_bib1","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.21873\/anticanres.12732","article-title":"Possible application of ascites-infiltrating gamma-delta T cells for adoptive immunotherapy","volume":"38","author":"Abe","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1124\/jpet.118.254979_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.254979_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/02841868909111182","article-title":"A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer","volume":"28","author":"Adams","year":"1989","journal-title":"Acta Oncol"},{"key":"10.1124\/jpet.118.254979_bib4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front Oncol"},{"key":"10.1124\/jpet.118.254979_bib5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res Lett"},{"key":"10.1124\/jpet.118.254979_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ygyno.2013.07.081","article-title":"Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer [published correction appears in Gynecol Oncol (2014) 134:216]","volume":"131","author":"Anwer","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1124\/jpet.118.254979_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ygyno.2009.11.020","article-title":"Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype","volume":"116","author":"Barnett","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1124\/jpet.118.254979_bib8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.118.254979_bib9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","article-title":"Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer","volume":"27","author":"Berek","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.118.254979_bib10","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/IGC.0000000000000286","article-title":"Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study","volume":"24","author":"Berek","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1124\/jpet.118.254979_bib11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.118.254979_bib12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0014-2964(78)90125-1","article-title":"Adriamycin in ovarian cancer patients resistant to cyclophosphamide","volume":"14","author":"Bolis","year":"1978","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.118.254979_bib13","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.4049\/jimmunol.178.3.1505","article-title":"Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy","volume":"178","author":"Bouzin","year":"2007","journal-title":"J Immunol"},{"key":"10.1124\/jpet.118.254979_bib14","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.7150\/jca.20314","article-title":"Immune cell population in ovarian tumor microenvironment","volume":"8","author":"Cai","year":"2017","journal-title":"J Cancer"},{"key":"10.1124\/jpet.118.254979_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-065X.1996.tb00919.x","article-title":"The role of CTLA-4 in the regulation and initiation of T-cell responses","volume":"153","author":"Chambers","year":"1996","journal-title":"Immunol Rev"},{"key":"10.1124\/jpet.118.254979_bib16","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.118.254979_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"10.1124\/jpet.118.254979_bib18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2005.10.027","article-title":"Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up","volume":"101","author":"Chou","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1124\/jpet.118.254979_bib19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.molmed.2017.05.003","article-title":"Exosomes as reconfigurable therapeutic systems","volume":"23","author":"Conlan","year":"2017","journal-title":"Trends Mol Med"},{"key":"10.1124\/jpet.118.254979_bib20","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.1016\/j.biomaterials.2012.06.011","article-title":"Paracrine signalling events in embryonic stem cell renewal mediated by affinity targeted nanoparticles","volume":"33","author":"Corradetti","year":"2012","journal-title":"Biomaterials"},{"key":"10.1124\/jpet.118.254979_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/IJWH.S52379","article-title":"New perspectives on targeted therapy in ovarian cancer","volume":"7","author":"Coward","year":"2015","journal-title":"Int J Womens Health"},{"key":"10.1124\/jpet.118.254979_bib22","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-11-3160","article-title":"Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer","volume":"72","author":"Cubillos-Ruiz","year":"2012","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.118.254979_bib23","first-page":"2231","article-title":"Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity","volume":"119","author":"Cubillos-Ruiz","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.118.254979_bib24","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","article-title":"ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis","volume":"161","author":"Cubillos-Ruiz","year":"2015","journal-title":"Cell"},{"key":"10.1124\/jpet.118.254979_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918778483","article-title":"Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy","volume":"10","author":"Dal Molin","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"16 Suppl","key":"10.1124\/jpet.118.254979_bib26","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/jco.2005.23.16_suppl.2048","article-title":"Final results of a phase I study of liposome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer","volume":"23","author":"Damjanov","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.118.254979_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2217\/17520363.2.3.291","article-title":"Early detection of ovarian cancer","volume":"2","author":"Das","year":"2008","journal-title":"Biomarkers Med"},{"key":"10.1124\/jpet.118.254979_bib28","doi-asserted-by":"crossref","first-page":"e104099","DOI":"10.1371\/journal.pone.0104099","article-title":"Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer","volume":"9","author":"Daudi","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.118.254979_bib29","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2217\/nnm.13.118","article-title":"Current trends in the use of liposomes for tumor targeting","volume":"8","author":"Deshpande","year":"2013","journal-title":"Nanomedicine (Lond)"},{"key":"10.1124\/jpet.118.254979_bib30","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41467-017-01217-9","article-title":"Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma","volume":"8","author":"Ducie","year":"2017","journal-title":"Nat Commun"},{"key":"10.1124\/jpet.118.254979_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4049\/jimmunol.190.Supp.205.14","article-title":"Co-delivery of adjuvant and subunit antigens via a nanoparticle platform induces tissue-associated and systemic adaptive immune responses (P4409)","volume":"190","author":"Dunkle","year":"2013","journal-title":"J Immunol"},{"key":"10.1124\/jpet.118.254979_bib32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41563-018-0094-5","article-title":"Adoptive T cell cancer therapy","volume":"17","author":"Dzhandzhugazyan","year":"2018","journal-title":"Nat Mater"},{"key":"10.1124\/jpet.118.254979_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CAD.0000000000000023","article-title":"Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer: a retrospective analysis","volume":"25","author":"Eitan","year":"2014","journal-title":"Anticancer Drugs"},{"key":"10.1124\/jpet.118.254979_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1615\/CritRevOncog.2014011455","article-title":"Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics","volume":"19","author":"Engelberth","year":"2014","journal-title":"Crit Rev Oncog"},{"key":"10.1124\/jpet.118.254979_bib35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14737140.2018.1490180","article-title":"Niraparib for the treatment of ovarian cancer","volume":"18","author":"Essel","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1124\/jpet.118.254979_bib36","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/vaccines3030662","article-title":"Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy","volume":"3","author":"Fan","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1124\/jpet.118.254979_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","article-title":"The role of immune checkpoint inhibition in the treatment of ovarian cancer","volume":"3","author":"Gaillard","year":"2016","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1124\/jpet.118.254979_bib38","doi-asserted-by":"crossref","first-page":"15772","DOI":"10.18632\/oncotarget.4694","article-title":"Oncogenic cancer\/testis antigens: prime candidates for immunotherapy","volume":"6","author":"Gjerstorff","year":"2015","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.118.254979_bib39","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ijgc-00009577-200211000-00004","article-title":"Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: a phase II study","volume":"12","author":"Gordinier","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1124\/jpet.118.254979_bib40","first-page":"229","article-title":"Pegylated liposomal doxorubicin in ovarian cancer","volume":"1","author":"Green","year":"2006","journal-title":"Int J Nanomedicine"},{"key":"10.1124\/jpet.118.254979_bib41","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.cell.2017.08.031","article-title":"Converting cold into hot tumors by combining immunotherapies","volume":"170","author":"Haanen","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1124\/jpet.118.254979_bib42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejpb.2013.07.002","article-title":"Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review","volume":"85","author":"Hadinoto","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1124\/jpet.118.254979_bib43","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/ajco.12074","article-title":"Oral cyclophosphamide in recurrent ovarian cancer","volume":"12","author":"Handolias","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1124\/jpet.118.254979_bib44","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1600-0897.2010.00968.x","article-title":"Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen","volume":"65","author":"Hanlon","year":"2011","journal-title":"Am J Reprod Immunol"},{"key":"10.1124\/jpet.118.254979_bib45","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/sj.bjc.6601044","article-title":"Oral melphalan as a treatment for platinum-resistant ovarian cancer","volume":"88","author":"Hasan","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.118.254979_bib46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/wnan.1228","article-title":"Polyethylenimines for siRNA and miRNA delivery in vivo","volume":"5","author":"H\u00f6bel","year":"2013","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1124\/jpet.118.254979_bib47","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/01.cad.0000167902.53039.5a","article-title":"Liposomal encapsulated anti-cancer drugs","volume":"16","author":"Hofheinz","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1124\/jpet.118.254979_bib48","doi-asserted-by":"crossref","first-page":"14684","DOI":"10.1038\/s41598-017-14661-w","article-title":"Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia","volume":"7","author":"Hong","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.118.254979_bib49","doi-asserted-by":"crossref","first-page":"20160054","DOI":"10.1098\/rsfs.2016.0054","article-title":"Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment","volume":"6","author":"Howard","year":"2016","journal-title":"Interface Focus"},{"key":"10.1124\/jpet.118.254979_bib50","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","article-title":"Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient","volume":"170","author":"Jim\u00e9nez-S\u00e1nchez","year":"2017","journal-title":"Cell"},{"key":"10.1124\/jpet.118.254979_bib51","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12032-018-1131-6","article-title":"Prospects of chimeric antigen receptor T cell therapy in ovarian cancer","volume":"35","author":"Jindal","year":"2018","journal-title":"Med Oncol"},{"key":"10.1124\/jpet.118.254979_bib52","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.bbamem.2007.01.019","article-title":"Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin","volume":"1768","author":"Johnston","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.118.254979_bib53","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2016.08.320","article-title":"Low-grade serous ovarian cancer: a review","volume":"143","author":"Kaldawy","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1124\/jpet.118.254979_bib54","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1479-5876-11-149","article-title":"A phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer","volume":"11","author":"Kandalaft","year":"2013","journal-title":"J Transl Med"},{"key":"10.1124\/jpet.118.254979_bib55","doi-asserted-by":"crossref","first-page":"e36967","DOI":"10.7554\/eLife.36967","article-title":"Topography of cancer-associated immune cells in human solid tumors","volume":"7","author":"Kather","year":"2018","journal-title":"eLife"},{"key":"10.1124\/jpet.118.254979_bib56","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/jvim.12596","article-title":"A review of paclitaxel and novel formulations including those suitable for use in dogs","volume":"29","author":"Khanna","year":"2015","journal-title":"J Vet Intern Med"},{"key":"10.1124\/jpet.118.254979_bib57","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrc3432","article-title":"Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research","volume":"13","author":"Kipps","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.118.254979_bib58","doi-asserted-by":"crossref","first-page":"52045","DOI":"10.18632\/oncotarget.19090","article-title":"Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-\u03b3 receptor engagement","volume":"8","author":"Kline","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.118.254979_bib59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.118.254979_bib60","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.4049\/jimmunol.180.11.7338","article-title":"Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D","volume":"180","author":"Krockenberger","year":"2008","journal-title":"J Immunol"},{"key":"10.1124\/jpet.118.254979_bib61","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3389\/fimmu.2017.01128","article-title":"Peripheral autoimmune regulator induces exhaustion of CD4+ and CD8+ effector T cells to attenuate autoimmune diabetes in non-obese diabetic mice","volume":"8","author":"Kulshrestha","year":"2017","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.118.254979_bib62","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1124\/jpet.118.254979_bib63","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.3802\/jgo.2017.28.e26","article-title":"An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016)","volume":"28","author":"Lee","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"10.1124\/jpet.118.254979_bib64","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/eji.200324228","article-title":"Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses","volume":"33","author":"Liang","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1124\/jpet.118.254979_bib65","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ygyno.2013.06.023","article-title":"Therapeutic vaccines for ovarian cancer","volume":"130","author":"Liao","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1124\/jpet.118.254979_bib66","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.118.254979_bib67","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.18632\/oncotarget.20812","article-title":"Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy","volume":"9","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.118.254979_bib68","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study","volume":"23","author":"Long","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1124\/jpet.118.254979_bib69","doi-asserted-by":"crossref","first-page":"v188","DOI":"10.1093\/annonc\/mdj979","article-title":"Role of gemcitabine in ovarian cancer treatment","volume":"17","author":"Lorusso","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1124\/jpet.118.254979_bib70","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/aps.2017.12","article-title":"Engineering exosomes as refined biological nanoplatforms for drug delivery","volume":"38","author":"Luan","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/jpet.118.254979_bib71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1615\/CritRevImmunol.2016017387","article-title":"Metabolic regulation of natural killer cell IFN-\u03b3 production","volume":"36","author":"Mah","year":"2016","journal-title":"Crit Rev Immunol"},{"key":"10.1124\/jpet.118.254979_bib72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fcell.2018.00018","article-title":"Exosome-based cell-cell communication in the tumor microenvironment","volume":"6","author":"Maia","year":"2018","journal-title":"Front Cell Dev Biol"},{"key":"10.1124\/jpet.118.254979_bib73","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/0008-5472.CAN-15-1737","article-title":"A breakthrough: macrophage-directed cancer immunotherapy","volume":"76","author":"Mills","year":"2016","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.118.254979_bib74","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/smll.201503484","article-title":"Biomimetic concealing of PLGA microspheres in a 3D scaffold to prevent macrophage uptake","volume":"12","author":"Minardi","year":"2016","journal-title":"Small"},{"key":"10.1124\/jpet.118.254979_bib75","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","article-title":"Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications","volume":"8","author":"Mirzaei","year":"2017","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.118.254979_bib76","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pharma.2011.10.001","article-title":"Platinum anticancer drugs. From serendipity to rational design","volume":"69","author":"Monneret","year":"2011","journal-title":"Ann Pharm Fr"},{"key":"10.1124\/jpet.118.254979_bib77","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.254979_bib78","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"key":"10.1124\/jpet.118.254979_bib79","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3389\/fimmu.2017.01178","article-title":"Natural killer T cells in cancer immunotherapy","volume":"8","author":"Nair","year":"2017","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.118.254979_bib80","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajog.2015.03.044","article-title":"New insights in the pathophysiology of ovarian cancer and implications for screening and prevention","volume":"213","author":"Nezhat","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/jpet.118.254979_bib81","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.trecan.2018.02.008","article-title":"Transport barriers and oncophysics in cancer treatment","volume":"4","author":"Nizzero","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1124\/jpet.118.254979_bib82","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1039\/C4NR03962A","article-title":"Biocompatible mannosylated endosomal-escape nanoparticles enhance selective delivery of short nucleotide sequences to tumor associated macrophages","volume":"7","author":"Ortega","year":"2015","journal-title":"Nanoscale"},{"key":"10.1124\/jpet.118.254979_bib83","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00262-018-2211-3","article-title":"Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells","volume":"67","author":"Owens","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1124\/jpet.118.254979_bib84","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ygyno.2005.07.030","article-title":"Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125","volume":"99","author":"Patankar","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1124\/jpet.118.254979_bib85","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ccell.2017.04.007","article-title":"Tumor microenvironment: no effector T cells without dendritic cells","volume":"31","author":"Pfirschke","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.118.254979_bib86","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1158\/1078-0432.CCR-14-2810","article-title":"Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer","volume":"21","author":"Pham","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.118.254979_bib87","doi-asserted-by":"crossref","first-page":"898146","DOI":"10.1155\/2013\/898146","article-title":"Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer","volume":"2013","author":"Pisano","year":"2013","journal-title":"J Drug Deliv"},{"key":"10.1124\/jpet.118.254979_bib88","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/imt.11.20","article-title":"Immunity and immune suppression in human ovarian cancer","volume":"3","author":"Preston","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1124\/jpet.118.254979_bib89","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2017.12.023","article-title":"Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate","volume":"271","author":"Rajan","year":"2018","journal-title":"J Control Release"},{"key":"10.1124\/jpet.118.254979_bib90","first-page":"15","article-title":"Ovarian cancer screening and early detection in the general population","volume":"4","author":"Rauh-Hain","year":"2011","journal-title":"Rev Obstet Gynecol"},{"key":"10.1124\/jpet.118.254979_bib91","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.118.254979_bib92","doi-asserted-by":"crossref","first-page":"12389","DOI":"10.18632\/oncotarget.13310","article-title":"Bevacizumab in ovarian cancer: a critical review of phase III studies","volume":"8","author":"Rossi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.118.254979_bib93","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/bjc.2017.199","article-title":"A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours","volume":"117","author":"Russell","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.118.254979_bib94","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res"},{"key":"10.1124\/jpet.118.254979_bib95","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2012.46.4057","article-title":"Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study","volume":"31","author":"Sabbatini","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"10.1124\/jpet.118.254979_bib96","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1186\/ar567","article-title":"The instructive role of dendritic cells on T-cell responses","volume":"27","author":"Sallusto","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1124\/jpet.118.254979_bib97","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jconrel.2016.10.014","article-title":"Precision targeted therapy of ovarian cancer","volume":"243","author":"Sapiezynski","year":"2016","journal-title":"J Control Release"},{"key":"10.1124\/jpet.118.254979_bib98","doi-asserted-by":"crossref","first-page":"709049","DOI":"10.1155\/2012\/709049","article-title":"Early detection biomarkers for ovarian cancer","volume":"2012","author":"Sarojini","year":"2012","journal-title":"J Oncol"},{"key":"10.1124\/jpet.118.254979_bib99","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1084\/jem.20111413","article-title":"Ovarian cancer progression is controlled by phenotypic changes in dendritic cells","volume":"209","author":"Scarlett","year":"2012","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.118.254979_bib100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2003.12.037","article-title":"A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer","volume":"93","author":"Seiden","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1124\/jpet.118.254979_bib101","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2217\/imt-2017-0154","article-title":"Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma","volume":"10","author":"Seifi-Alan","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1124\/jpet.118.254979_bib102","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1158\/1078-0432.CCR-12-2764","article-title":"Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery","volume":"19","author":"Shen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.118.254979_bib103","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.smim.2017.09.002","article-title":"Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells","volume":"34","author":"Shen","year":"2017","journal-title":"Semin Immunol"},{"key":"10.1124\/jpet.118.254979_bib104","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1021\/acsanm.8b00601","article-title":"Tracking exosomes in vitro and in vivo to elucidate their physiological functions: implications for diagnostic and therapeutic nanocarriers","volume":"1","author":"Shen","year":"2018","journal-title":"ACS Applied Nano Materials"},{"key":"10.1124\/jpet.118.254979_bib105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1124\/jpet.118.254979_bib106","article-title":"Ovarian cancer ascites induces a T cell suppressive phenotype in mature neutrophils: a potential barrier to anti-tumor immunity","volume":"198","author":"Singel","year":"2017","journal-title":"J Immunol"},{"key":"10.1124\/jpet.118.254979_bib107","first-page":"940591","article-title":"Combination therapy of albumin-bound paclitaxel and carboplatin as first line therapy in a patient with ovarian cancer","volume":"2014","author":"Srinivasan","year":"2014","journal-title":"Case Rep Oncol Med"},{"key":"10.1124\/jpet.118.254979_bib108","doi-asserted-by":"crossref","first-page":"24436","DOI":"10.1038\/srep24436","article-title":"Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node","volume":"6","author":"Srinivasan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.118.254979_bib109","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2298\/AOO0402115S","article-title":"Pathogenesis of malignant ascites in ovarian cancer patients","volume":"12","author":"Stanojevic","year":"2004","journal-title":"Arch Oncol"},{"key":"10.1124\/jpet.118.254979_bib110","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.tibtech.2017.03.004","article-title":"Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges","volume":"35","author":"Syn","year":"2017","journal-title":"Trends Biotechnol"},{"key":"10.1124\/jpet.118.254979_bib111","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","article-title":"Mechanisms of transcoelomic metastasis in ovarian cancer","volume":"7","author":"Tan","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1124\/jpet.118.254979_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1124\/jpet.118.254979_bib113","doi-asserted-by":"crossref","first-page":"44312","DOI":"10.18632\/oncotarget.17871","article-title":"The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer","volume":"8","author":"Tayama","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.118.254979_bib114","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1016\/j.biomaterials.2013.07.005","article-title":"Hydrophobic modification of low molecular weight polyethylenimine for improved gene transfection","volume":"34","author":"Teo","year":"2013","journal-title":"Biomaterials"},{"key":"10.1124\/jpet.118.254979_bib115","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/adhm.201500089","article-title":"Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing","volume":"4","author":"Teo","year":"2015","journal-title":"Adv Healthc Mater"},{"key":"10.1124\/jpet.118.254979_bib116","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/1078-0432.CCR-16-0316","article-title":"A prospective evaluation of early detection biomarkers for ovarian cancer in the european EPIC cohort","volume":"22","author":"Terry","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.118.254979_bib117","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2017.10.030","article-title":"No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in The Netherlands","volume":"88","author":"Timmermans","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.118.254979_bib118","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1124\/jpet.118.254979_bib119","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.canlet.2003.12.028","article-title":"Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma","volume":"213","author":"Turk","year":"2004","journal-title":"Cancer Lett"},{"key":"10.1124\/jpet.118.254979_bib120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1600-0897.2012.01113.x","article-title":"The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia","volume":"68","author":"Tyler","year":"2012","journal-title":"Am J Reprod Immunol"},{"key":"10.1124\/jpet.118.254979_bib121","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40824-018-0132-z","article-title":"Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications","volume":"22","author":"Uthaman","year":"2018","journal-title":"Biomater Res"},{"key":"10.1124\/jpet.118.254979_bib122","first-page":"375","article-title":"Cancer immunotherapy, part 1: current strategies and agents","volume":"42","author":"Ventola","year":"2017","journal-title":"PT"},{"key":"10.1124\/jpet.118.254979_bib123","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1517\/14712598.2011.566854","article-title":"Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature","volume":"11","author":"Whitworth","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1124\/jpet.118.254979_bib124","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.celrep.2015.04.009","article-title":"Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response","volume":"11","author":"Xia","year":"2015","journal-title":"Cell Rep"},{"key":"10.1124\/jpet.118.254979_bib125","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nbt.3506","article-title":"An injectable nanoparticle generator enhances delivery of cancer therapeutics","volume":"34","author":"Xu","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.118.254979_bib126","doi-asserted-by":"crossref","first-page":"13325","DOI":"10.1038\/ncomms13325","article-title":"Theranostic barcoded nanoparticles for personalized cancer medicine","volume":"7","author":"Yaari","year":"2016","journal-title":"Nat Commun"},{"key":"10.1124\/jpet.118.254979_bib127","doi-asserted-by":"crossref","first-page":"75","DOI":"10.15430\/JCP.2014.19.2.75","article-title":"Endoplasmic reticulum stress and cancer","volume":"19","author":"Yadav","year":"2014","journal-title":"J Cancer Prev"},{"key":"10.1124\/jpet.118.254979_bib128","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1248\/bpb.b18-00133","article-title":"Possibility of exosome-based therapeutics and challenges in production of exosomes eligible for therapeutic application","volume":"41","author":"Yamashita","year":"2018","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/jpet.118.254979_bib129","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11427-016-5027-4","article-title":"Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci China Life Sci"},{"key":"10.1124\/jpet.118.254979_bib130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.254979_bib131","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1021\/mp2003797","article-title":"Lipoic acid modified low molecular weight polyethylenimine mediates nontoxic and highly potent in vitro gene transfection","volume":"8","author":"Zheng","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.118.254979_bib132","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.drudis.2018.02.012","article-title":"Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts","volume":"23","author":"Zheng","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1124\/jpet.118.254979_bib133","doi-asserted-by":"crossref","first-page":"64607","DOI":"10.18632\/oncotarget.19929","article-title":"CAR-T cell therapy in ovarian cancer: from the bench to the bedside","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.118.254979_bib134","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.118.254979_bib135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1084\/jem.183.1.87","article-title":"Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines","volume":"183","author":"Zitvogel","year":"1996","journal-title":"J Exp Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524260365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524260365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.118.254979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:52:45Z","timestamp":1739994765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524260365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":135,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0022356524260365"],"URL":"https:\/\/doi.org\/10.1124\/jpet.118.254979","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.118.254979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}